Palvella Therapeutics Announces Proposed Public Offering

Core Viewpoint - Palvella Therapeutics, Inc. has initiated a public offering of $150 million in common stock to support the development of its therapies for rare skin diseases and vascular malformations, with an additional option for underwriters to purchase $22.5 million more [1][3]. Group 1: Offering Details - The public offering consists of $150 million in common stock, with a 30-day option for underwriters to purchase an additional $22.5 million [1]. - The offering is subject to market conditions and is being conducted under a shelf registration statement effective since January 29, 2026 [4]. - Joint bookrunning managers for the offering include TD Cowen, Cantor, Stifel, Mizuho, LifeSci Capital, Oppenheimer & Co., Canaccord Genuity, and H.C. Wainwright & Co. [2]. Group 2: Use of Proceeds - Net proceeds from the offering will be utilized to advance the development of Palvella's programs, specifically QTORIN rapamycin and QTORIN pitavastatin, as well as for working capital and general corporate purposes, including research and development expenses [3]. Group 3: Company Overview - Palvella Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for serious, rare skin diseases and vascular malformations without FDA-approved treatments [6]. - The company is developing a pipeline based on its patented QTORIN™ platform, with its lead product candidate being QTORIN™ 3.9% rapamycin anhydrous gel for treating microcystic lymphatic malformations and other conditions [6]. - QTORIN™ pitavastatin is another product candidate aimed at treating disseminated superficial actinic porokeratosis [6].